About AVRA Medical Robotics
Creating intelligent medical robotic systems
AVRA Medical Robotics, Inc. ( OTC: AVMR ) is revolutionizing the practice of medicine by developing a fully autonomous surgical robotic system that “robotizes” a wide range of medical procedures currently being performed by human hands using surgical and non-surgical devices and instruments. AVRA is concentrating its research and development efforts to meet rising expectations of patients and practitioners alike for the precision, safety and speed offered by robotics and artificial intelligence when combined with proven medical devices and surgical instruments.
AVRA Press Releases
ORLANDO, FL – May 26, 2021 – AVRA Medical Robotics’ Chief Medical Officer to Reveal Company’s Latest Developments in Surgical Robots at Global Conference
ORLANDO, FL – February 11, 2021 – AVRA Medical Robotics, Inc. (OTCMKTS: AVMR)
2020 Year-End CEO Update Letter to Shareholders and the Investment Community
ORLANDO, FL – January 28, 2021 – AVRA Medical Robotics, Inc. (OTC: AVMR) Engages New Auditors.
ORLANDO, FL – February 3, 2020 – AVRA Medical Robotics Clears Debt
ORLANDO, FL – January 17, 2020 – AVRA Medical Robotics Attends J.P. Morgan Healthcare Conference
ORLANDO, FL – September 20, 2019 – AVRA Medical Robotics Appoints Two World Renowned Professionals to Chair its Medical and Scientific Advisory Boards
ORLANDO, FL – August 28, 2019 – AVRA Medical Robotics Initiates Food and Drug Administration Approval Process
NEWPORT BEACH, CA – July 24, 2019 – oVio Technologies Partners With AVRA Medical Robotics to Automate Procedures
ORLANDO, FL – July 8, 2019 – AVRA Medical Robotics Announces its Participation in 10th Annual Meeting of the Society of Robotic Surgery
AVRA Corporate Updates
On January 31, 2019 AVRA Medical Robotics’ CEO Mr. Barry Cohen released letter to update Shareholders
On July 31, 2017 the S1 was deemed effective by the SEC.
On February 14, 2017, AVRA filed a Registration on Form S-1 with the U.S. Securities and Exchange Commission covering the resale of certain of our outstanding shares of common stock with a view to becoming a fully reporting public company.